Novartis (NVS -1.17%) is one of the planet's top drug manufacturers and its 3% dividend yield makes it a staple in dividend investor portfolios.
However, Novartis is facing significant threats from competitors Biogen Idec (BIIB 2.92%) and Regeneron (REGN -1.15%) which could crimp sales even as generic competition heats up for Novartis' multi-billion blockbuster drug Diovan.
Source: Novartis
In the following slideshow, you'll learn more about Novartis' most important drugs and the threats and opportunities the lie ahead for them.
